Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups

Mattiolo, Paola; Gkountakos, Anastasios; Centonze, Giovanni; Bevere, Michele; Piccoli, P; Ammendola, Serena; Pedrazzani, Corrado; Landoni, Luca; Cingarlini, Sara; Milella, Michèle; Milione, Massimo; Luchini, Claudio; Scarpa, Aldo; Simbolo, Michele

doi:10.1016/j.prp.2023.154674

Cited by 1 publication

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, different tumor methylation profiles are able to stratify a patient’s risk [ 128 , 130 , 131 ]. Similarly, transcriptomic profiles have been reported to identify distinct subgroups characterized by different biology and potential therapeutic targets [ 132 ]. In addition, gene expression profiling, supported by functional analysis in cell lines and animal models, has identified EZH2 as a candidate oncogene in JINET, with important potential implications for therapy, as EZH2 is a target for metformin [ 133 ].…”

Section: Molecular Features Of Digestive Netmentioning

confidence: 99%

Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?

Uccella

2024

Endocr Pathol

View full text Add to dashboard Cite

In the last two decades, the increasing availability of technologies for molecular analyses has allowed an insight in the genomic alterations of neuroendocrine neoplasms (NEN) of the gastrointestinal tract and pancreas. This knowledge has confirmed, supported, and informed the pathological classification of NEN, clarifying the differences between neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) and helping to define the G3 NET category. At the same time, the identification genomic alterations, in terms of gene mutation, structural abnormalities, and epigenetic changes differentially involved in the pathogenesis of NEC and NET has identified potential molecular targets for precision therapy. This review critically recapitulates the available molecular features of digestive NEC and NET, highlighting their correlates with pathological aspects and clinical characteristics of these neoplasms and revising their role as predictive biomarkers for targeted therapy. In this context, the feasibility and applicability of a molecular classification of gastrointestinal and pancreatic NEN will be explored.

show abstract

Section: Molecular Features Of Digestive Netmentioning

confidence: 99%

Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?

Uccella

2024

Endocr Pathol

View full text Add to dashboard Cite

show abstract

Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups

Cited by 1 publication

References 44 publications

Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?

Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?

Contact Info

Product

Resources

About